Table 4 Randomized studies comparing... | American Society of Hematology

Table 4

Randomized studies comparing conventional chemotherapy versus high-dose therapy

Author (reference)	No. of patients	Age, y	Median follow up	CR rate, %		Median EFS, mo		Median OS, mo
Author (reference)	No. of patients	Age, y	Median follow up	CC	HDT	CC	HDT	CC	HDT
Attal et al¹⁸	200	< 65	7 y	5*	22*	18*	28*	44*	57*
Fermand et al³⁶	190	55-65	56 mo	5*	19*	19*	24*	50	55
Bladé et al³⁹	164	< 65	44 mo	11*	30*	33	42	66	61
Palumbo et al³⁷	195	< 70	39 mo	6*	25*	15.6*	28*	42*	58*
Child et al²⁶	407	< 65	42 mo	8*	44*	19*	31*	42*	54*
Fermand et al³⁸	190	55-65	10 y	20 CR + VGPR*	48 CR + VGPR*	19†	25†	48	48
Barlogie et al⁴⁰	516	≤ 70	76 mo	15	17	7 y 14%	7 y 17%	7 y 38%	7 y 38%

Author (reference)	No. of patients	Age, y	Median follow up	CR rate, %		Median EFS, mo		Median OS, mo
Author (reference)	No. of patients	Age, y	Median follow up	CC	HDT	CC	HDT	CC	HDT
Attal et al¹⁸	200	< 65	7 y	5*	22*	18*	28*	44*	57*
Fermand et al³⁶	190	55-65	56 mo	5*	19*	19*	24*	50	55
Bladé et al³⁹	164	< 65	44 mo	11*	30*	33	42	66	61
Palumbo et al³⁷	195	< 70	39 mo	6*	25*	15.6*	28*	42*	58*
Child et al²⁶	407	< 65	42 mo	8*	44*	19*	31*	42*	54*
Fermand et al³⁸	190	55-65	10 y	20 CR + VGPR*	48 CR + VGPR*	19†	25†	48	48
Barlogie et al⁴⁰	516	≤ 70	76 mo	15	17	7 y 14%	7 y 17%	7 y 38%	7 y 38%

Significant.

†

Borderline significance.

y indicates years; CR, complete response; EFS, event-free survival; OS, overall survival; CC, conventional chemotherapy; HDT, high-dose therapy; mo, months; and VGPR, very good partial response.

View Large

This Feature Is Available To Subscribers Only